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Survival extrapolation in cancer immunotherapy: a validation-based case study 
Bullement A, Latimer NR, Bell Gorrod H. 
Abstract 
243/250 words 
Objectives: Immune-checkpoint inhibitors may provide long-term survival benefits via a 
cured proportion, yet data are usually insufficient to prove this upon submission to health 
technology assessment bodies. We revisit the National Institute for Health and Care 
Excellence assessment of ipilimumab in melanoma (TA319). We use updated data from the 
pivotal trial to assess the accuracy of the extrapolation methods used and compare these to 
previously-unused techniques to establish whether an alternative extrapolation may have 
provided more accurate survival projections.  
Methods: We compare projections from the piecewise survival model used in TA319 and 
those produced by alternative models (fit to trial data with minimum follow-up of 3 years), to 
a longer-term data-cut (5-year follow-up). We also compare projections to external data to 
help assess validity. Alternative approaches considered were parametric, spline-based, 
mixture, and mixture-cure-models.  
Results: Only the survival model used in TA319 and a mixture-cure model provided 5-year 
survival predictions close to those observed in the 5-year follow-up dataset. Standard 
parametric, spline, and non-curative-mixture models substantially under-estimated 5-year 
survival. Survival estimates from the TA319 model and the mixture-cure model diverge 
considerably after 5 years and remain unvalidated.   
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Conclusions: In our case study, only models that incorporated an element of external 
information (through a cure fraction combined with background mortality rates or using 
registry data) provided accurate estimates of 5-year survival. Flexible models that were able 
to capture the complex hazard functions observed during the trial, but which did not 
incorporate external information, extrapolated poorly.  
Highlights 
x Extrapolations of survival for cancer immunotherapies are associated with substantial 
uncertainty, and often emerge as a key concern when cancer immunotherapies are 
appraised by the National Institute for Health and Care Excellence (NICE).  
x No previous study has attempted to validate extrapolations from early data-cuts of 
cancer immunotherapy trials via comparison to later data-cuts.  
x Through comparing projections from an early data-cut to actual survival from a later 
data-cut, we show that in this case study seemingly optimistic extrapolations may in 
fact be credible. Assessing extrapolation fit to new data is useful for providing 
evidence on the performance of extrapolation methods.   
Main body 
3,984/4,000 words 
Introduction 
Immunotherapy is an area of ever-evolving research in the treatment of cancer, most recently 
with the development of immune-checkpoint inhibitors (ICIs) ± a type of monoclonal 
antibody which aims to enhance the immune system to destroy cancer cells. (1-3) ICIs may 
result in a proportion of patients achieving long-term survival outcomes, sometimes referred 
to as a ³statistically-cured´ fraction. (4-11) However, ICI registrations are characterised by 
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clinical trials with limited follow-up, and hence there is a great deal of uncertainty as to 
whether there truly is a ³statistically-cured´ fraction yet to be observed. Decision-makers are 
consequently placed in a difficult position, given that the estimation of survival (and whether 
or not this includes a ³statistically-cured´ fraction) plays a huge role in determining an 
LQWHUYHQWLRQ¶VFOLQLFDODQGFRVWHIIHFWLYHQHVV 
The National Institute for Health and Care Excellence (NICE) published guidance on the first 
licensed ICI ipilimumab for patients with treatment-naïve advanced melanoma in July 2014 
(TA319). (12-14) As part of TA319, the manufacturer submitted a cost-effectiveness analysis 
(CEA) based on data from the pivotal CA184-024 trial with a minimum follow-up period of 
37 months (henceforth referred to as 3 years). (15) The survival extrapolation used in TA319 
combined registry data for patients not treated with ipilimumab with CA184-024 data in a 
piecewise approach. Following publication of TA319, further follow-up data (5-year 
minimum follow up) have been published from CA184-024. (16, 17) 
The NICE Decision Support Unit (DSU) first published guidance regarding survival analysis 
and extrapolation using patient-level data (PLD) in June 2011 in the form of Technical 
Support Document (TSD) 14. (18) TSD-14 IRFXVHVPDLQO\RQVL[³VWDQGDUG´SDUDPHWULF
distributions (exponential, Weibull, Gompertz, log-normal, log-logistic and generalized 
gamma). Other methods are also discussed in TSD-14 (e.g. piecewise and flexible parametric 
models) though only in brief. More recently, mixture- and spline-based models have been 
presented on several occasions in the literature. (19-21) These newer methods were not well 
known in the world of health technology assessment (HTA) around the time of TA319. 
The aim of this study is to assess the survival predictions obtained from the piecewise model 
used in TA319 compared to those from a range of alternative models. Models are fit to the 3-
year data-cut (available at the time of TA319), and predicted survival is compared to 
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observed survival in the 5-year data-cut. This allows an assessment of how well each model 
estimates 5-year survival. Projections are also compared to long-term survival trends in 
melanoma exhibited in registry data to provide information on their credibility beyond 5 
years. 
Methods 
The dataset 
The CA184-024 trial compared ipilimumab + dacarbazine (IPI+DTIC) to placebo + 
dacarbazine (PBO+DTIC) in treatment-naïve advanced melanoma. (15) CA184-024 was a 
multi-centre, randomised, double-blind, Phase III study of 502 adult stage III/IV melanoma 
patients. (15) PLD for overall survival were recreated from published 3-year and 5-year 
Kaplan-Meier (KM) curves using an algorithm by Guyot et al. (22) The recreated PLD were 
required in order to fit and subsequently compare alternative survival extrapolations, as the 
³WUXH´3/'DUHQRWSXEOLFO\DYDLODEOHIn the 3-year data-cut 47 patients treated with 
IPI+DTIC and 28 patients treated with PBO+DTIC remained at risk at 3 years. In the 5-year 
data-cut 40 patients treated with IPI+DTIC and 18 patients treated with PBO+DTIC were at 
risk at 5 years.  
Candidate models 
The model used in TA319 incorporated three piecewise components: (1) the KM curve from 
CA184-024 to inform survival until 2 years; (2) a log-normal curve fitted to patients alive in 
CA184-024 beyond 2 years to inform survival from 2 until 5 years; and (3) a Weibull curve 
fitted to long-term registry data from the American Joint Committee on Cancer (AJCC) to 
inform survival beyond 5 years. (12) The same approach was adopted for both treatment 
arms, such that the hazard of death for all patients was equal after 5 years. 
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In addition to the TA319 piecewise model, we considered ³standard´SDUDPHWULFVXUYLYDO
models, Royston and Parmar spline-based models, and mixture models. Standard parametric 
survival and piecewise models are well documented in published literature, and therefore are 
not discussed in detail here. (18, 23-26) However, the other candidate models are less well 
known, and therefore brief overviews of the models are provided: 
Spline-based models consider extensions of the Weibull, log-normal and log-logistic 
distributions where natural cubic splines (piecewise polynomials) are used to smooth between 
piecewise sections of the model. (27) Gibson et al. (20) have previously considered these 
models in the context of ICIs ± fitting standard parametric and spline-based models to 
progression-free survival data from the CheckMate-067 trial of nivolumab and ipilimumab in 
advanced melanoma and concluding that the spline-based models were able to characterise a 
IODWWHQLQJRIWKHVXUYLYDOFXUYHD³SODWHDX´observed within the data.  
Mixture models have been considered within the literature to reflect the apparent 
heterogeneity evident in populations of patients, whereby separate groups have different 
underlying survival distributions. Chen (28) and Othus et al. (21) present parametric mixture-
cure models (MCMs) as a method to quantify the expectation that a group of ICI patients may 
achieve long-term survival. The parametric MCMs consider two separate survival 
trajectories, estimating D³VWDWLVWLFDOO\-FXUHG´SURSRUWLRQRISDWLHQWV (determined via logistic 
regression). That is, a proportion of patients die from their disease, and a proportion of 
patients will follow the survival trajectory that would be expected for the age-adjusted 
general population and do not die of their disease. We considered log-normal and Weibull 
0&0¶VDQGLQFRUSRUDWHGEDFNJURXQGPRUWDOLW\IURP8QLWHG.LQgdom (UK) age- and sex-
matched life tables from the Office for National Statistics (ONS), assuming baseline mean 
patient characteristics from CA184-024. (29) 
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Another example of a mixture model is the mixture-Weibull model (MWM). Sánchez et al. 
(30) utilised the MWM for the survival of immunotherapy-treated advanced non-small-cell 
OXQJFDQFHUSDWLHQWVDQG&URZWKHUHWDOXVHGWKH0:0WRILWWR³FRPSOH[
VXUYLYDOGDWD´ZLWKDQH[DPSOHLQEUHDVWFDQFHU7KH0:0GHPRQVWUDWHVLPSURYHGYLVXDO
fit versus the standard Weibull model in the latter of these examples. These mixture models 
permit different survival distributions to exist within the data, but do not assume a 
³VWDWLVWLFDOO\-cureG´ fraction. We considered the MWM in this study but no other non-cure-
based mixture models. 
Selecting potentially appropriate models 
In order to assess the potential suitability of the models, we assessed the recreated PLD using 
a variety of techniques. First, we evaluated the underlying hazard function in order to 
establish the suitability of models that assume proportional hazards (PH models) or constant 
acceleration factors (accelerated failure time [AFT] models). Second, we used the hazard 
function to assess the applicability of standard parametric forms (such as the exponential, 
which assumes a constant hazard rate). Third, we used the hazard function to identify turning 
points to inform the appropriate number of knots in the spline-based models. Models 
considered potentially suitable were fitted to the 3-year re-created PLD using the statistical 
software packages R and Stata. (32, 33) 
Assessing model predictions 
Following model fitting, an assessment of each model was undertaken. The fit to the 
observed data (via visual inspection and/or residual analysis) was first considered. Next, the 
plausibility and credibility of survival extrapolation was ascertained through comparing 
trajectories to external data and background mortality rates. Finally, the statistical goodness-
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models that incorporate an inefficient use of additional parameters to inform their estimation 
of survival. This process of selecting appropriate survival models is in line with TSD-14 
recommendations. (18) 
In TA319 long-term survival data for advanced melanoma patients treated with non-ICI 
treatment available from the AJCC were used to inform survival projections. (34) These data 
provided estimates of 15-year survival which may be considered useful when ascertaining 
whether or not survival projections demonstrate clinical plausibility. Baseline characteristics 
for patients in CA184-024 are published however the corresponding data for AJCC patients 
are unreported. (15, 34) Therefore, the comparability of the AJCC and CA184-024 data is 
unclear. 
To assess the survival predictions made by the different fitted models we compared these to 
the 5-year CA184-024 data-cut, the AJCC data, and mortality rates for the UK age- and sex-
matched general population. (29) In particular, the AJCC data were used to assess the 
plausibility of survival extrapolations for the control arm; noting the previous reporting 
limitations and acknowledging the ages of the respective studies. 
Results 
Survival observed in CA184-024 
The re-created KM curves are presented in Figure 1 for the 3- and 5-year data-cuts. Median 
survival for patients treated with PBO+DTIC in the 3-year data-cut was approximately 9.1 
versus 11.2 months for IPI+DTIC. (15) 5-year survival in the 5-year data-cut was 18.2% for 
IPI+DTIC patients versus 8.8% for PBO+DTIC patients. (16) 
Estimated smoothed hazard functions for both data-cuts are also presented in Figure 1. 
Hazards originally increased, before decreasing in the longer-term in both treatment arms. 
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There was an apparent increase close to the end of trial-follow-up in the 3-year data-cut for 
patients treated with IPI+DTIC, but this is highly uncertain due to the small number of 
patients at risk at this point (and indeed this increase was not present in the 5-year data-cut).  
In CA184-024, patients were required to have a life expectancy of at least 16 weeks prior to 
treatment initiation, (15) and so a low initial hazard of death may be expected. However, 
given the severity of advanced melanoma, the hazard of death would be expected to increase 
following the start of the study. In the longer term however, patients with a better prognosis 
(i.e. responders) would still be alive, and so the hazard of death for the surviving group of 
patients would fall. Further in the future, the hazard of death may increase again as patients 
age (though this may be difficult to determine due to trial follow-up and patient numbers). 
Based upon the hazard functions estimated in the 3-year data-cut for both treatment arms we 
deemed that only parametric models that can represent increasing and then decreasing (i.e. 
non-monotonic) hazards were appropriate. Models that assume either constant or 
unidirectional (monotonic) hazards would provide a poor representation of the observed data. 
This meant the exponential, Gompertz and Weibull distributions were inappropriate for 
consideration. 
The smoothed hazard function also demonstrates that the treatment effect does not appear to 
be proportional (this was also suggested by log-cumulative hazard and quantile-quantile 
plots, not presented here) and therefore models were fitted to treatment arms independently. 
Based on CA184-024 data, and the assessment of the corresponding smoothed hazard plot, 
the following candidate models were considered potentially appropriate and were fitted: (1) 
Log-normal, log-logistic, generalised gamma and generalised-F parametric survival models; 
(2) Spline-based models; (3) MCMs; and (4) MWM.  
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The number of turning points in the smoothed hazard plot was used to determine the number 
of knots for the spline-based models. Models with one or two knots were considered as a 
maximum of two turning points were evident in the hazard plot. 3-knot models were 
considered, though provided substantially poorer statistical goodness-of-fit scores and are 
therefore not presented. The best fitting one- and two-knot spline-based models (in terms of 
AIC and BIC) were the odds- and hazard-based splines, respectively; and so were considered 
henceforth. The knot locations were determined according to percentiles of the uncensored 
survival times, in line with recommendations. (27)  
The statistical goodness-of-fit for each survival model is presented in Table 1. All models 
were also considered in terms of their visual fit to the observed data, shown in Figure 2. Each 
of the models exhibited a reasonable fit to the observed data, though by year 5 there is a clear 
spread of projected survival estimates ranging from 10%-18%. 
Survival beyond the observed period of CA184-024  
Predicted survival proportions at 3, 5, 10, 15 years, and mean survival estimates associated 
with each model/ data source are presented in Table 2. The corresponding survival curves are 
presented in Figure 2, alongside KM curves from the 5-year data-cut of CA184-024 and 
AJCC data. 
The TA319 piecewise model yielded a mean survival estimate of 3.59 life-years for 
IPI+DTIC patients and 2.50 life-years for PBO+DTIC patients ± greater than all the other 
models except for the two MCMs. 
2QO\WKH7$SLHFHZLVHPRGHODQGWKH0&0¶VSURYLGH5-year survival probabilities close 
to those observed for  IPI+DTIC in the 5-year data-cut (17.5%, 17.4% and 14.4% for the 
TA319 model, Weibull MCM and log-normal MCM respectively, compared to 18.1% 
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observed in the 5-year data-cut). The parametric models, MWM and spline-based models 
under-predict 5-year survival for IPI+DTIC (ranging from 10.1% to 13.2%). Beyond 5 years 
the survival predicted for IPI+DTIC by the TA319 model and the MCMs diverge 
considerably. The flattened shape of the survival curves predicted by the MCMs appears to 
be more in line with survival at 6 years observed in the 5-year data-cut from CA184-24, but 
beyond this point the IPI+DTIC curves remain unvalidated. 
In contrast, the TA319 model and the MCMs appear to over-estimate 5-year survival for the 
PBO+DTIC group (11.0%, 11.1% and 9.1% for the TA319 model, Weibull MCM and log-
normal MCM respectively, compared to 8.1% observed in the 5-year data-cut). The 
parametric and spline-based models provide under-estimates of 5-year survival for 
PBO+DTIC, whereas the MWM provides an accurate estimate. However, the AJCC data 
suggests that the survival curve may be expected to flatten somewhat even for the 
PBO+DTIC group ± the MWM does not follow this trend. The log-normal MCM and the 
TA319 model are the only models that appear to project survival in a way that is consistent 
with the AJCC data.   
Figure 3 (see Supplementary Material) presents the estimated hazard of death for both groups 
of patients projected by each model, as well as those estimated based on the observed data 
from CA184-024 (5-year data-cut) and ONS background mortality rates. All models except 
the MWM, the MCMs and the TA319 piecewise model demonstrate decreasing hazards 
beyond 5 years. The MWM and the TA319 models both include a Weibull component which 
exhibits monotonically increasing hazards. For the MCMs the hazard increases in the longer-
term because increasing age-related hazards are accounted for. Only the MCMs result in 
extrapolations in which mortality beyond approximately 5-10 years is represented by 
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background mortality rates ± all other approaches exhibit hazards that are substantially higher 
than background mortality.  
Discussion 
The MCMs and the piecewise approach used in TA319 were the only models that provided 
extrapolations for IPI+DTIC that were aligned with the 5-year data-cut from CA184-024. 
These also predicted the highest mean survival for IPI+DTIC. Flexible models, such as the 
spline-based models and the MWM, were able to represent non-monotonic hazards but 
appeared to over-estimate longer-term hazards. 
The AJCC data suggest 15-year survival for patients not treated with IPI+DTIC is 
approximately 4.2%. (34) This is of limited use for assessing survival predictions for patients 
treated with IPI+DTIC, but may be considered to represent a lower bound for potentially 
credible extrapolations. Only the two MCMs and the TA319 piecewise model predicted 15-
year survival of at least 4.2% for both treatment arms.  
For PBO+DTIC patients, several methods predicted 5-year survival in line with the 5-year 
data-cut. However, predictions of survival differed substantially in the longer-term, with 15-
year survival estimates ranging from 0.5% (MWM) to 9.8% (Weibull MCM). Several models 
exhibited a distinct lack of face validity, predicting 10-year survival of less than 3% and all 
models except the MCMs and the TA319 piecewise model predicted lower long-term 
survival than that observed in the AJCC data.  
While CA184-024 data show survival for PBO+DTIC to be lower than the AJCC survival 
curve in the short-term, the gap appeared to narrow according to the 5-year data-cut. It 
appears that the Weibull MCM may over-estimate longer-term survival for PBO+DTIC  
patients, whereas the TA319 piecewise approach and the log-normal MCM appear to provide 
12 
more credible estimates. However, the aforementioned limitations of the AJCC data remain. 
As such, the estimate of 15-year survival for PBO+DTIC patients of 10% provided by the 
Weibull MCM may not be completely unrealistic. 
In this study we identified that the underlying hazard functions estimated for the 3-year data-
cut were complex, and that only models that could account for turning points in the hazard 
function would yield appropriate extrapolations. Accordingly, we fit a range of potentially 
appropriate models, but found that several of these did not provide accurate estimates of 5-
year survival based upon a subsequent data-cut. Only models that incorporated external 
information (MCMs through background mortality data, and the TA319 piecewise model 
through the use of mortality rates from the AJCC registry) were able to accurately predict 5-
year survival whilst also providing a survival curve with the shape expected based upon long-
term registry data. This strengthens previous suggestions around the use of external 
information in survival extrapolation. (35, 36) 
Our analysis also provides further evidence illustrating the substantial impact that the 
extrapolation method can have on mean survival estimates, which in turn are likely to have an 
important effect on CEA results. Within the context of a treatment with potential long-term 
survival benefits, the importance of selecting an appropriate survival extrapolation method is 
heightened.  
Our case study appears to offer support for the use of M&0¶VZKLFKVKRZRQHRIWKHEHVW
fits to the 5-year data-cut, and exhibit estimates of longer-term hazards in line with registry 
data. However, these models also provided the largest estimates of survival and at the time 
HTA decisions are made there may be an understandable reluctance to believe such 
optimistic estimates. In addition, we have demonstrated that the parameterisation of an MCM 
has an important impact on survival projections ± the Weibull and log normal MCMs 
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produced substantially different extrapolations ± illustrating how sensitive extrapolations are 
to the ³VWDWLVWLFDOO\-cureG´ fraction estimated, which may also vary by parameterisation. 
Given the small patient numbers that usually remain at the end of follow-up in clinical trials ± 
which is key for estimating the ³VWDWLVWLFDOO\-FXUHG´ fraction ± caution is certainly required 
when using MCMs in a clinical trial context.    
In TA319 a piecewise modelling approach was taken which appears to have produced 
accurate estimates of 5-year survival, and results in longer estimates of mean survival than 
most other models. However, our analyses suggest that even these estimates may have been 
pessimistic for IPI+DTIC, and optimistic for PBO+DTIC patients. The specification of a 
piecewise model requires the analyst to specify relevant cut-points at which to fit different 
models (in this case study, the model was cut at 2 and 5 years). Davies et al. (26) 
demonstrated how the choice of these cut-points can have a profound effect on the overall 
extrapolation produced, and the choice of cut-points for piecewise models is frequently 
criticised within NICE technology appraisals (including TA319). (12, 37, 38) The same 
criticism may be raised for spline-based models (in relation to knot locations) ± whilst this 
may not be critical for model fit, (27) it may have an important effect on extrapolations. 
Despite their limitations, we have shown that the piecewise approach and MCMs appear to 
have performed relatively well in our case study. We contend that it is not a coincidence that 
these were the only two methods that incorporated external information in some form. Other 
approaches may have provided similarly plausible longer-term survival estimates if they were 
adapted to include similar external information. For instance, spline-based models can be 
ILWWHGLQDUHODWLYHVXUYLYDOIUDPHZRUNZKHUHE\³GLVHDVH-VSHFLILFPRUWDOLW\´DQG³RWKHU-cause 
PRUWDOLW\´DUHPRGHOOHGVHSDUDWHO\ZLWKLQIRUPDWLRQRQEDFNJURXQGPRUWDOLW\LQFRUSRUDWHG
IRUWKHODWWHUFRPSRQHQW:KHUH³GLVHDVH-VSHFLILFPRUWDOLW\´UDWHVIDOOWR]HURD
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statistical cure is essentially modelled, potentially resulting in the kind of survival curve 
plateau observed in the 5-year data-cut and in the AJCC registry data. A limitation of our 
work is that we did not attempt to fit such models ± but further use of these in an HTA and 
extrapolation context should be explored.  
Recreated PLD were used to fit survival models in this study, and so extrapolation methods 
WKDWUHTXLUH³WUXH´3/'ZHUHQRWFRQVLGHUHGIRUH[DPSOHUHVSRQVH-based models discussed 
by Huang et al.) $FFHVVWR³WUXH´3/'ZRXOGDOORZIRUimproved accuracy of model 
fitting, adjustment for covariates and the ability to consider more complex models. However, 
the use of recreated PLD does not impede the fitting of survival models in general, and 
consequently provides a sufficient basis to compare survival projections. 
Our study demonstrates that it is useful to collect longer-term information from clinical trials 
in order that the accuracy of previous extrapolations can be assessed ± such updates should be 
encouraged whenever long-term survival is expected but not proven. (6) Further data 
collection from the same trial may be requested by NICE relating to a conditional approval 
via the Cancer Drugs Fund, or a periodic review of guidance (for TA319, this was scheduled 
2 years following publication of the Final Appraisal Determination). (12) 
However, whilst continued publication of updated survival information is highly 
commendable, the 5-year data-cut from CA184-024 unavoidably remains limited to a 
relatively short time period, compared to the potential survival times of ³VWDWLVWLFDOO\-FXUHG´ 
survivors. It is striking that even models that produce similar estimates of survival at 5 years 
go on to project considerably different mean survival, for both treatment arms. In particular, 
even in the 5-year data-cut the existence of a ³VWDWLVWLFDOO\-FXUHG´ fraction is still unclear, 
though published literature suggest that conditional survival appears to improve over time in 
melanoma ± Xing et al. (41) reported that conditional 5-year survival for stage IV melanoma 
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patients increased from 19% upon diagnosis to 84% if patients survive until 5 years, based on 
data from the Surveillance, Epidemiology, and End Results (SEER) Program (though these 
patients did not receive ICI treatment).  
It should be further acknowledged that this study reports the findings of one case study in 
advanced melanoma. We have shown that cure-based models may represent a useful tool for 
projecting survival when long-term survival is expected in a proportion of patients. However, 
WKHSUHVHQFHRID³FXUHIUDFWLRQ´LVQRWHYLGHQFHRID³true´ cure. Publication of updated data-
cuts from clinical trials in which long-term survival is expected would allow further 
investigation of whether or not a true cure is evident, which in turn may provide additional 
justification for undertaking survival modelling using cure-based models. Subsequently, 
decision-makers may have more confidence in basing decisions on analyses that assume that 
a proportion of patients are truly cured.  
TSD-14 was last updated in 2013. (18) Since then, a number of ICIs have been assessed by 
NICE which have adopted increasingly complex extrapolation methods ± recently NICE 
TA590 of nivolumab for unresectable/ metastatic urothelial cancer included the use of a 
response-based model (combined with a landmark analysis to overcome immortal time bias) 
as standard models would ³fail to capture the changes in hazard over time´. (42) Our case 
study provides an overview of different extrapolation methods (some of which are not 
discussed within TSD-14), which may aid the future update of guidance. However, it was not 
possible to consider all methods and only data from CA184-024 were considered, hence 
further research is required to provide comprehensive guidance for the fitting of complex 
survival models.  
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Conclusions 
Our study demonstrates how updated clinical trial data-cuts can be used to assess the 
accuracy of extrapolations made by fitting survival models to earlier data-cuts. This provides 
useful information on which models appear to extrapolate well, and which appear to 
extrapolate inaccurately. We only consider one case study, but the findings are useful more 
broadly, and are of particular relevance in diseases where long-term survival is expected.  
Flexible models that are able to accurately represent complex hazard functions are likely to 
provide a good fit to observed data but may not extrapolate accurately ± in our study these 
methods under-estimated 5-year survival for IPI+DTIC. Models that incorporated external 
information ± either by assuming a ³VWDWLVWLFDOO\-FXUHG´ fraction and incorporating 
background mortality rates, or by extrapolating in line with longer-term registry data ± 
provided more accurate estimates of 5-year survival, demonstrating the importance of 
including relevant external information when available. However, even these models 
projected beyond 5 years very differently, demonstrating the need to continue to collect 
survival data in order to further aid understanding of long-term survival.   
  
References 
1. Dine J, Gordon R, Shames Y, et al. Immune Checkpoint Inhibitors: An Innovation in 
Immunotherapy for the Treatment and Management of Patients with Cancer. Asia Pac J 
Oncol Nurs. 2017; 4: 127-35. 
2. Cancer Research UK (CRUK). What are 'checkpoint' immunotherapy drugs? 
(YouTube video). 2015. 
17 
3. Couzin-Frankel J. Cancer Immunotherapy. Science. 2013; 342: 1432. 
4. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and 
carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a 
randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 2012; 30: 2046-54. 
5. +RGL)62¶'D\6-0F'HUPRWW')HWDO,PSURYHG6XUYLYDOZLWK,SLOLPXPDELQ
Patients with Metastatic Melanoma. N. Engl. J. Med.. 2010; 363: 711-23. 
6. Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival 
Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic 
Melanoma. J. Clin. Oncol. 2015; 33: 1889-94. 
7. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus 
Chemotherapy for PD-L1±Positive Non±Small-Cell Lung Cancer. N. Engl. J. Med. 2016; 
375: 1823-33. 
8. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced 
Squamous-Cell Non±Small-Cell Lung Cancer. N. Engl. J. Med. 2015; 373: 123-35. 
9. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-
refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 
trial. Lancet Oncol. 2016; 17: 1374-85. 
10. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with 
locally advanced and metastatic urothelial carcinoma who have progressed following 
treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 
2016; 387: 1909-20. 
18 
11. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in 
Stage III Non±Small-Cell Lung Cancer. N. Engl. J. Med. 2017; 377: 1919-29. 
12. National Institute for Health and Care Excellence (NICE). TA319: Ipilimumab for 
previously untreated unresectable malignant melanoma. 2014. 
13. Leach DR, Krummel MF, Allison JP. Enhancement of Antitumor Immunity by 
CTLA-4 Blockade. Science. 1996; 271: 1734-36. 
14. European Medicines Agency (EMA). EPAR summary for the public: Yervoy 
(ipilimumab). 2013. 
15. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus Dacarbazine for 
Previously Untreated Metastatic Melanoma. N. Engl. J. Med. 2011; 364: 2517-26. 
16. Maio M, Grob J-J, Aamdal S, et al. Five-Year Survival Rates for Treatment-Naive 
Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase 
III Trial. J. Clin. Oncol. 2015; 33: 1191-96. 
17. Maio M, Bondarenko I, Robert C, et al. Four-year Survival Update for Metastatic 
Melanoma (MM) Patients (pts) (IPI) + Dacarbazine (DTIC) Treated With Ipilimumab in 
Phase 3 Study CA184-024. 37th European Society for Medical Oncology (ESMO) Congress. 
Vienna: Austria, 2012. 
18. Latimer N. NICE DSU Technical Support Document 14: Undertaking survival 
analysis for economic evaluations alongside clinical trials - extrapolation with patient-level 
data. 2011. 
19 
19. Huang M, Latimer NR, Zhang Y, et al. Estimating the Long-Term Outcomes 
Associated With ImmunoOncology Therapies: Challenges and Approaches for Overall 
Survival Extrapolations. Value & Outcomes Spotlight. 2018; 4. 
20. Gibson E, Koblbauer I, Begum N, et al. Modelling the Survival Outcomes of 
Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data 
Analysis and Extrapolation. PharmacoEconomics. 2017. 
21. Othus M, Bansal A, Koepl L, et al. Accounting for Cured Patients in Cost-
Effectiveness Analysis. Value Health. 2017; 20: 705-09. 
22. Guyot P, Ades A, Ouwens M, et al. Enhanced secondary analysis of survival data: 
reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. 
Methodol. 2012; 12: 9. 
23. Tremblay G, Livings C, Crowe L, et al. Determination of the most appropriate 
method for extrapolating overall survival data from a placebo-controlled clinical trial of 
lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. Clin. 
Outcomes Res. 2016; 8: 323-33. 
24. Collett D. Modelling survival data in medical research. 2 ed.: Boca Raton: Chapman 
& Hall, 2003. 
25. Latimer NR. Survival Analysis for Economic Evaluations Alongside Clinical Trials²
Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide. 
Med. Decis. Making. 2013; 33: 743-54. 
20 
26. Davies A, Briggs A, Schneider J, et al. The Ends Justify the Mean: Outcome 
Measures for Estimating the Value of New Cancer Therapies. Health Outcomes Res. Med. 
2012; 3: e25-e36. 
27. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-
odds models for censored survival data, with application to prognostic modelling and 
estimation of treatment effects. Stat. Med. 2002; 21: 2175-97. 
28. Chen T-T. Predicting analysis times in randomized clinical trials with cancer 
immunotherapy. BMC Med. Res. Methodol. 2016; 16: 12. 
29. Office for National Statistics (ONS). Dataset: National Life Tables: United Kingdom. 
2016. 
30. Sánchez L, Muchene L, Luaces P, et al. Evaluating the effect of immunotherapy in 
advanced non-small-cell lung cancer patients using two components mixture model. ISPOR 
17th Annual European Congress. Amsterdam: The Netherlands, 2014. 
31. Crowther MJ, Lambert PC. Simulating complex survival data. Stata Nordic and Baltic 
8VHUV¶*URXS0HHWLQJ6WRFNKROP6ZHGHQ 
32. R Core Team. R: A language and environment for statistical computing. R Foundation 
for Statistical Computing. Vienna, Austria. 2013. 
33. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP. 
2013. 
34. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint 
Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001; 19: 
3635-48. 
21 
35. Guyot P, Ades AE, Beasley M, et al. Extrapolation of Survival Curves from Cancer 
Trials Using External Information. Med. Decis. Making. 2017; 37: 353-66. 
36. Jackson C, Stevens J, Ren S, et al. Extrapolating Survival from Randomized Trials 
Using External Data: A Review of Methods. Med. Decis. Making. 2017; 37: 377-90. 
37. National Institute for Health and Care Excellence (NICE). Technology appraisal 
guidance ID925: Alectinib for untreated anaplastic lymphoma kinase-positive advanced non-
small-cell lung cancer. 2018. 
38. Andersson TM, Dickman PW, Eloranta S, et al. Estimating the loss in expectation of 
life due to cancer using flexible parametric survival models. Stat. Med. 2013; 32: 5286-300. 
39. Andersson TM, Dickman PW, Eloranta S, et al. Estimating and modelling cure in 
population-based cancer studies within the framework of flexible parametric survival models. 
BMC Med. Res. Methodol. 2011; 11: 96. 
40. Dickman PW, Sloggett A, Hills M, et al. Regression models for relative survival. Stat. 
Med. 2004; 23: 51-64. 
41. Xing Y, Chang GJ, Hu CY, et al. Conditional survival estimates improve over time 
for patients with advanced melanoma: results from a population-based analysis. Cancer. 
2010; 116: 2234-41. 
42. National Institute for Health and Care Excellence (NICE). TA590: Nivolumab for 
treating metastatic or unresectable urothelial cancer after platinum-based chemotherapy. 
2018. 
 
22 
Table 1 ± Statistical goodness of fit for survival models 
Parameterisation AIC BIC 
(1) Parametric survival models 
Generalised-F 3,105.29 3,133.50 
Generalised Gamma 3,108.95 3,130.10 
Log-logistic 3,108.99 3,126.62 
Log-normal 3,107.53 3,121.63 
(2) Spline-based models 
Odds ± 1-knot 3,100.05 3,116.93 
Normal ± 1-knot 3,106.56 3,123.43 
Hazard ± 1-knot  3,101.06 3,117.94 
Odds ± 2-knots 3,100.45 3,121.54 
Normal ± 2-knots 3,099.97 3,121.06 
Hazard ± 2-knots  3,098.99 3,120.09 
(3) Mixture-cure models 
Weibull 3,053.43 3,063.36 
Log-normal 3,024.60 3,034.70 
(4) Mixture-Weibull model 
Mixture-Weibull model 3,110.93 3,113.03 
 
Table 2 ± Mean survival estimates for each data source and survival extrapolation 
Data source 
Survival (%) RMST 
(years) 
Maximum 
time 
(years) 3 years 5 years 10 years 15 years 
CA184-024 
(Original) 
IPI + DTIC 
PBO + DTIC 
21.2 
12.9 - - - 
1.4747 
1.2106 4 
CA184-024 
(Updated) 
IPI + DTIC 
PBO + DTIC 
22.1 
12.0 
18.1 
8.1 - - 
1.7957 
1.3591 6 
AJCC registry 16.1 10.6 7.0 4.2 1.9838 15 
Extrapolation Survival (%) Mean survival (years)  3 years 5 years 10 years 15 years Total ǻ 
TA319 PM IPI + DTIC PBO + DTIC 
22.2 
14.9 
17.5 
11.0 
11.1 
6.9 
7.0 
4.4 
3.5597 
2.4995 1.0602 
Weibull MCM IPI + DTIC PBO + DTIC 
20.4 
12.3 
17.4 
11.1 
16.4 
10.5 
15.1 
9.8 
5.4738 
3.7267 1.7471 
Log-normal MCM IPI + DTIC PBO + DTIC 
20.8 
13.5 
14.4 
9.1 
10.5 
6.8 
9.2 
6.1 
4.0389 
2.8750 1.1639 
Generalised 
gamma 
IPI + DTIC 
PBO + DTIC 
20.8 
12.5 
12.3 
5.8 
5.4 
1.6 
3.1 
0.6 
2.6843 
1.5717 1.1127 
Spline - 2 knot - 
Hazard 
IPI + DTIC 
PBO + DTIC 
21.0 
13.7 
13.2 
7.9 
5.6 
2.9 
2.9 
1.4 
2.5970 
1.7844 0.8126 
Log-logistic IPI + DTIC PBO + DTIC 
18.5 
11.3 
10.1 
5.5 
4.1 
2.0 
2.4 
1.1 
2.4079 
1.6369 0.7709 
Generalised-F IPI + DTIC PBO + DTIC 
20.8 
13.1 
12.5 
7.7 
5.8 
3.8 
3.6 
2.5 
2.8168 
2.0924 0.7245 
Log-normal IPI + DTIC PBO + DTIC 
19.5 
12.3 
10.2 
5.5 
3.3 
1.4 
1.5 
0.5 
2.2095 
1.5385 0.6709 
Spline - 1 knot - 
Odds 
IPI + DTIC 
PBO + DTIC 
21.0 
12.8 
12.5 
7.0 
4.6 
2.9 
2.1 
1.7 
2.4003 
1.8644 0.5359 
MWM IPI + DTIC PBO + DTIC 
21.2 
13.4 
11.3 
8.1 
1.5 
2.1 
0.1 
0.5 
1.9706 
1.6170 0.3536 
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Figure 1: Reconstructed Kaplan-Meier plots of overall survival in CA184-024 and smoothed 
hazard plot for patients in CA184-024 (both data-cuts)  
Key: DTIC, dacarbazine; IPI, ipilimumab; PBO, placebo. 
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Figure 2: Overview of fitted models within observed period and extrapolation of survival. 
Description: A: Short-term fit to observed data for ipilimumab + dacarbazine; B: Long-term 
extrapolation of survival for ipilimumab + dacarbazine; C: Short-term fit to observed data for 
placebo + dacarbazine; D: Long-term extrapolation of survival for placebo + dacarbazine.  
Key: AJCC, American Joint Committee on Cancer; KM, Kaplan-Meier; MCM, mixture-cure 
model; MWM, mixture-Weibull model; ONS, Office for National Statistics; TA, Technology 
Appraisal.  
 
 
 
 
